Diatomaceous earth lowers blood cholesterol concentrations
- PMID: 9533930
Diatomaceous earth lowers blood cholesterol concentrations
Abstract
In this study a potential influence of diatomaceus earth to lower blood cholesterol was investigated. During 12 weeks we monitored serum lipid concentrations in 19 healthy individuals with a history of moderate hypercholesterinemia (9 females, 10 males, aged 35 - 67 years). Individuals administered orally 250 mg diatomaceous earth three-times daily during an 8 weeks observation period. Serum concentrations of cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides levels were measured before study entry, every second week during the period of diatomaceous earth intake and 4 weeks after stop of intake. Compared to baseline (285.8 +/- 37.5 mg/dl = 7.40 +/- 0.97 mM) diatomaceous earth intake was associated with a significant reduction of serum cholesterol at any time point, reaching a minimum on week 6 (248.1 mg/dl = 6.43 mM, -13.2% from baseline; p<0.001). Also low-density lipoprotein cholesterol (week 4: p<0.05) and triglycerides levels decreased (week 2: p<0.05, week 4: p<0.01). Four weeks after intake of diatomaceous earth was stopped, serum cholesterol, low-density lipoprotein cholesterol and triglycerides still remained low and also the increase of high-density lipoprotein cholesterol became significant (p<0.05). Diatomaceous earth, a bioproduct, is capable of reducing blood cholesterol and positively influencing lipid metabolism in humans. Placebo-controlled studies will be necessary to confirm our findings.
Similar articles
-
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.Clin Ther. 2004 Nov;26(11):1758-73. doi: 10.1016/j.clinthera.2004.11.016. Clin Ther. 2004. PMID: 15639688 Clinical Trial.
-
Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.J Am Osteopath Assoc. 2002 Jul;102(7):377-84. J Am Osteopath Assoc. 2002. PMID: 12138952 Clinical Trial.
-
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.Clin Ther. 2008 Jun;30(6):1089-101. doi: 10.1016/j.clinthera.2008.05.017. Clin Ther. 2008. PMID: 18640465 Clinical Trial.
-
A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.Indian Heart J. 2003 May-Jun;55(3):234-40. Indian Heart J. 2003. PMID: 14560932
-
Relationship between blood triglyceride levels and periodontal status.Community Dent Health. 2004 Mar;21(1):32-6. Community Dent Health. 2004. PMID: 15074870
Cited by
-
Oral intake of mesoporous silica is safe and well tolerated in male humans.PLoS One. 2020 Oct 2;15(10):e0240030. doi: 10.1371/journal.pone.0240030. eCollection 2020. PLoS One. 2020. PMID: 33007031 Free PMC article. Clinical Trial.
-
Biotemplated Synthesis and Characterization of Mesoporous Nitric Oxide-Releasing Diatomaceous Earth Silica Particles.ACS Appl Mater Interfaces. 2018 Jan 24;10(3):2291-2301. doi: 10.1021/acsami.7b15967. Epub 2018 Jan 11. ACS Appl Mater Interfaces. 2018. PMID: 29278482 Free PMC article.
-
Surface functionalized amorphous nanosilica and microsilica with nanopores as promising tools in biomedicine.Naturwissenschaften. 2009 Jan;96(1):31-8. doi: 10.1007/s00114-008-0445-1. Epub 2008 Sep 13. Naturwissenschaften. 2009. PMID: 18791695
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical